AF
RXRX icon

Avanza Fonder’s Recursion Pharmaceuticals RXRX Stock Holding History

Avanza Fonder’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-86,342
Closed -$457K – 477
2025
Q1 		$457K Buy
86,342
+482
+0.6% +$3.51K 0.02% 390
2024
Q4 		$580K Buy
+85,860
New +$577K 0.02% 368

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Avanza Fonder's RXRX Position: Q2 2025 in Review

Avanza Fonder sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 86,342 shares — an estimated $457K sold.

Avanza Fonder first reported a position in RXRX in Q4 2024 and held it in 2 quarters. The position peaked at $580K in Q4 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Avanza Fonder reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Avanza Fonder sold 86,342 Recursion Pharmaceuticals shares in Q2 2025, an estimated $457K.
  • Avanza Fonder first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Avanza Fonder's Recursion Pharmaceuticals position peaked at $580K in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Avanza Fonder's 13F filing for Q2 2025, filed 14 Jul 2025.